Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?

Ketoconazole is a strong inhibitor of cytochrome P450 3A4 (CYP3A4) and of P-glycoprotein (P-gp) and is often used as an index inhibitor especially for CYP3A4-mediated drug metabolism. A preliminary physiologically based pharmacokinetic (PBPK) model for drug-drug interactions indicated possible invol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Weiß, Johanna (VerfasserIn) , Foerster, Kathrin (VerfasserIn) , Weber, Maria (VerfasserIn) , Burhenne, Jürgen (VerfasserIn) , Mikus, Gerd (VerfasserIn) , Lehr, Thorsten (VerfasserIn) , Haefeli, Walter E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022
In: European journal of pharmaceutical sciences
Year: 2022, Jahrgang: 169, Pages: 1-8
ISSN:1879-0720
DOI:10.1016/j.ejps.2021.106076
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejps.2021.106076
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S092809872100378X
Volltext
Verfasserangaben:Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, Jürgen Burhenne, Gerd Mikus, Thorsten Lehr, Walter Emil Haefeli

MARC

LEADER 00000caa a2200000 c 4500
001 1810554853
003 DE-627
005 20250109051319.0
007 cr uuu---uuuuu
008 220715s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ejps.2021.106076  |2 doi 
035 |a (DE-627)1810554853 
035 |a (DE-599)KXP1810554853 
035 |a (OCoLC)1341463935 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Weiß, Johanna  |e VerfasserIn  |0 (DE-588)1050230906  |0 (DE-627)783666322  |0 (DE-576)404441114  |4 aut 
245 1 0 |a Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?  |c Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, Jürgen Burhenne, Gerd Mikus, Thorsten Lehr, Walter Emil Haefeli 
264 1 |c 2022 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 29 November 2021 
500 |a Gesehen am 15.07.2022 
520 |a Ketoconazole is a strong inhibitor of cytochrome P450 3A4 (CYP3A4) and of P-glycoprotein (P-gp) and is often used as an index inhibitor especially for CYP3A4-mediated drug metabolism. A preliminary physiologically based pharmacokinetic (PBPK) model for drug-drug interactions indicated possible involvement of a metabolite to the perpetrator potential of ketoconazole. Still unknown for humans, in rodents, N-deacetyl ketoconazole (DAK) has been identified as the major ketoconazole metabolite. We therefore investigated in vitro, whether DAK also inhibits the human CYPs and drug transporters targeted by ketoconazole and quantified DAK in human plasma from healthy volunteers after receiving a single oral dose of 400 mg ketoconazole. Our data demonstrated that DAK also inhibits CYP3A4 (2.4-fold less potent than ketoconazole), CYP2D6 (13-fold more potent than ketoconazole), CYP2C19 (equally potent), P-gp (3.4-fold less potent than ketoconazole), breast cancer resistance protein (more potent than ketoconazole) and organic anion transporting polypeptide 1B1 and 1B3 (7.8-fold and 2.6-fold less potent than ketoconazole). After a single oral dose of 400 mg ketoconazole, maximum concentrations of DAK in human plasma were only 3.1 ‰ of the parent compound. However, assuming that DAK also highly accumulates in the human liver as demonstrated for rodents, inhibition of the proteins investigated could also be conceivable in vivo. In conclusion, DAK inhibits several CYPs and drug transporters, which might contribute to the perpetrator potential of ketoconazole. 
650 4 |a CYP 
650 4 |a Drug transporters 
650 4 |a Drug-drug interaction 
650 4 |a Ketoconazole 
650 4 |a N-deacetyl ketoconazole 
650 4 |a UPLC-MS/MS 
700 1 |a Foerster, Kathrin  |e VerfasserIn  |0 (DE-588)118114602X  |0 (DE-627)1662507089  |4 aut 
700 1 |a Weber, Maria  |e VerfasserIn  |4 aut 
700 1 |a Burhenne, Jürgen  |d 1963-  |e VerfasserIn  |0 (DE-588)1034228889  |0 (DE-627)745126987  |0 (DE-576)381858197  |4 aut 
700 1 |a Mikus, Gerd  |e VerfasserIn  |0 (DE-588)110903137  |0 (DE-627)691097941  |0 (DE-576)336988710  |4 aut 
700 1 |8 1\p  |a Lehr, Thorsten  |d 1977-  |e VerfasserIn  |0 (DE-588)132457830  |0 (DE-627)69060050X  |0 (DE-576)299158802  |4 aut 
700 1 |a Haefeli, Walter E.  |d 1958-  |e VerfasserIn  |0 (DE-588)124572359  |0 (DE-627)656806141  |0 (DE-576)340514221  |4 aut 
773 0 8 |i Enthalten in  |t European journal of pharmaceutical sciences  |d New York, NY [u.a.] : Elsevier, 1993  |g 169(2022), Artikel-ID 106076, Seite 1-8  |h Online-Ressource  |w (DE-627)300897308  |w (DE-600)1483522-8  |w (DE-576)094142033  |x 1879-0720  |7 nnas  |a Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? 
773 1 8 |g volume:169  |g year:2022  |g elocationid:106076  |g pages:1-8  |g extent:8  |a Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? 
856 4 0 |u https://doi.org/10.1016/j.ejps.2021.106076  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S092809872100378X  |x Verlag  |z lizenzpflichtig  |3 Volltext 
883 |8 1\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
951 |a AR 
992 |a 20220715 
993 |a Article 
994 |a 2022 
998 |g 124572359  |a Haefeli, Walter E.  |m 124572359:Haefeli, Walter E.  |d 910000  |d 910100  |e 910000PH124572359  |e 910100PH124572359  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 110903137  |a Mikus, Gerd  |m 110903137:Mikus, Gerd  |d 910000  |d 910100  |d 50000  |e 910000PM110903137  |e 910100PM110903137  |e 50000PM110903137  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 5 
998 |g 1034228889  |a Burhenne, Jürgen  |m 1034228889:Burhenne, Jürgen  |d 910000  |d 910100  |e 910000PB1034228889  |e 910100PB1034228889  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 118114602X  |a Foerster, Kathrin  |m 118114602X:Foerster, Kathrin  |d 910000  |d 910100  |e 910000PF118114602X  |e 910100PF118114602X  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1050230906  |a Weiß, Johanna  |m 1050230906:Weiß, Johanna  |d 910000  |d 910100  |d 50000  |e 910000PW1050230906  |e 910100PW1050230906  |e 50000PW1050230906  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1810554853  |e 4166626515 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Available online 29 November 2021","Gesehen am 15.07.2022"],"recId":"1810554853","person":[{"family":"Weiß","given":"Johanna","roleDisplay":"VerfasserIn","role":"aut","display":"Weiß, Johanna"},{"family":"Foerster","given":"Kathrin","roleDisplay":"VerfasserIn","role":"aut","display":"Foerster, Kathrin"},{"family":"Weber","role":"aut","roleDisplay":"VerfasserIn","given":"Maria","display":"Weber, Maria"},{"family":"Burhenne","display":"Burhenne, Jürgen","given":"Jürgen","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Mikus","display":"Mikus, Gerd","roleDisplay":"VerfasserIn","role":"aut","given":"Gerd"},{"given":"Thorsten","role":"aut","roleDisplay":"VerfasserIn","display":"Lehr, Thorsten","family":"Lehr"},{"display":"Haefeli, Walter E.","given":"Walter E.","roleDisplay":"VerfasserIn","role":"aut","family":"Haefeli"}],"language":["eng"],"id":{"eki":["1810554853"],"doi":["10.1016/j.ejps.2021.106076"]},"name":{"displayForm":["Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, Jürgen Burhenne, Gerd Mikus, Thorsten Lehr, Walter Emil Haefeli"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"2022"}],"physDesc":[{"extent":"8 S."}],"relHost":[{"title":[{"title_sort":"European journal of pharmaceutical sciences","title":"European journal of pharmaceutical sciences","subtitle":"official journal of the European Federation for Pharmaceutical Sciences"}],"language":["eng"],"disp":"Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?European journal of pharmaceutical sciences","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1993-","publisher":"Elsevier","dateIssuedKey":"1993","publisherPlace":"New York, NY [u.a.]"}],"note":["Gesehen am 25.05.2020","Ungezählte Beil.: Supplement"],"part":{"text":"169(2022), Artikel-ID 106076, Seite 1-8","pages":"1-8","extent":"8","year":"2022","volume":"169"},"recId":"300897308","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1993 -"],"id":{"issn":["1879-0720"],"eki":["300897308"],"zdb":["1483522-8"]},"titleAlt":[{"title":"Pharmaceutical sciences"}]}],"title":[{"title_sort":"Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?","title":"Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?"}]} 
SRT |a WEISSJOHANDOESTHECIR2022